E-LIB Suche - Ergebnisse für: Uyl-de Groot, Carin A

1

New systemic treatment paradigms in resectable non-small ce..:

Houda, Ilias ; Dickhoff, Chris ; Uyl-de Groot, Carin A....
The Lancet Regional Health - Europe. 38 (2024) - p. 100840 , 2024

Link: https://doi.org/10.1016/..

2

Market entry agreements for innovative pharmaceuticals subj..:

Heine, Renaud J.S.D. ; Mathijssen, Ron H.J. ; Verbeek, Floor A.J...
Value in Health. , 2024

Link: https://doi.org/10.1016/..

3

A health technology assessment of personalized nutrition in..:

Galekop, Milanne Maria Johanna ; del Bas, Josep Maria ; Calder, Philip C...
International Journal of Technology Assessment in Health Care. 40 (2024) 1 - p. , 2024

Link: https://doi.org/10.1017/..

4

Non-contrast short MRI surveillance for HCC screening: the ..:

van de Braak, Céline ; Willemssen, François E. J. A. ; de Man, Rob A....
European Radiology Experimental. 8 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

5

Broadening the HTA of medical AI: A review of the literatur..:

Boverhof, Bart-Jan ; Redekop, W. Ken ; Visser, Jacob J...
Health Policy and Technology. 13 (2024) 2 - p. 100868 , 2024

Link: https://doi.org/10.1016/..

6

Unraveling elements of value-based pricing from a pharmaceu..:

Dane, Aniek ; Uyl-de Groot, Carin ; van der Kuy, Hugo
Frontiers in Pharmacology. 15 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

7

Assessing the clinical benefit of systemic anti-cancer trea..:

Leeneman, Brenda ; Xander, Nicolas S.H. ; Fiets, W. Edward...
European Journal of Cancer. 202 (2024) - p. 114002 , 2024

Link: https://doi.org/10.1016/..

8

The Role of Medical Societies and the Relevance of Clinical..:

Julian, Elaine ; Solà-Morales, Oriol ; Garcia, Maria João...
Journal of Market Access & Health Policy. 12 (2024) 3 - p. 128-143 , 2024

Link: https://doi.org/10.3390/..

9

Challenges and controversies in resectable non-small cell l..:

Houda, Ilias ; Dickhoff, Chris ; Uyl-de Groot, Carin A....
The Lancet Regional Health - Europe. 38 (2024) - p. 100841 , 2024

Link: https://doi.org/10.1016/..

10

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Pa..:

Jongbloed, Elisabeth M ; Blommestein, Hedwig M ; van Schoubroeck, Hannah M...
Breast Cancer: Targets and Therapy. 15 (2023) - p. 147-161 , 2023

Link: https://doi.org/10.2147/..

11

Prices of Orphan Drugs in Four Western European Countries B..:

Dane, Aniek ; Klein Gebbink, Anne-Sophie ; Brugma, Jan-Dietert...
Applied Health Economics and Health Policy. 21 (2023) 6 - p. 905-914 , 2023

Link: https://doi.org/10.1007/..

12

R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly d..:

Chamuleau, Martine E D ; Stenner, Frank ; Chitu, Dana A...
The Lancet Haematology. 10 (2023) 12 - p. e966-e975 , 2023

Link: https://doi.org/10.1016/..

13

Cost-effectiveness and budget impact of pembrolizumab+axiti..:

Xander, Nicolas S. H. ; Fiets, W. Edward ; Uyl-de Groot, Carin A.
Frontiers in Oncology. 13 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

14

Economic Evaluation of a Personalized Nutrition Plan Based ..:

Galekop, Milanne Maria Johanna ; Uyl-de Groot, Carin ; Redekop, William Ken
PharmacoEconomics - Open. 8 (2023) 2 - p. 313-331 , 2023

Link: https://doi.org/10.1007/..

15

Reliability and Efficiency of the CAPRI-3 Metastatic Prosta..:

Bosch, Dianne ; Kuppen, Malou C. P. ; Tascilar, Metin...
Cancers. 15 (2023) 15 - p. 3808 , 2023

Link: https://doi.org/10.3390/..